---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-24-000067"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2024-06-05T23:59:59+00:00"
generated_at: "2026-06-01T06:16:05.997519+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Acumen stockholders elect two Class III directors, ratify Ernst & Young as auditor for FY2024

## Summary
- Daniel O'Connell received 40,490,834 votes for, 48,338 withheld; Nathan Fountain 34,164,444 for, 6,371,549 withheld.
- Ratification of Ernst & Young as auditor: 52,367,645 for, 7,093 against, 6,271 abstained.
- Approximately 87% of outstanding shares (52,381,009 of 60,079,778) were present at the annual meeting.
- Directors elected to serve until the 2027 annual meeting.

## SEC filing metadata
- accession: 0001576885-24-000067
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2024-06-05T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000067/0001576885-24-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688524000067/abos-20240604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-24-000067
- JSON: https://secwatch.observer/filing/0001576885-24-000067.json
- Plain text: https://secwatch.observer/filing/0001576885-24-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.